ERBB2 and breast cancer: Thus, both our in vitro and in vivo data seem to indicate that the ability of MM-121 to enhance the therapeutic efficacy of paclitaxel against erbB2-overexpressing breast cancer may be restricted to the ineffective doses of paclitaxel.